Thu 11/21/2019 14:35 ET
DJIA27818.832.780.01%TELCO187.570.960.51%GOLD1463.8510.390.71%Shanghai2903.647.260.25%
S&P 5003108.300.310.01%BANKS495.822.330.47%OIL58.591.582.70%BITCOIN7628.48370.744.86%
NASDAQ8519.736.820.08%PHARM578.103.990.69%US/EU1.110.000.00%Futures3106.882.170.07%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Pinks and BB    Pinks And BB Top Stock Picks

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  
From: efbailey (Rep: 1756)Date: 10/18/2019 14:36
Forum: Pinks and BB - Msg #137873Thread #674104009 (Rec: 0)
Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

https://onlinelibrary.wiley.com/doi/full/10.1111/epi.16355#.XalgB0OjSwc.twitter

There is an urgent need to introduce better treatment options for intractable epilepsies, particularly for Dravet syndrome, since less than 30% of patients respond to first‐line treatments.26-28 CBD has been shown to attenuate seizures in a mouse model of Dravet syndrome and reduce seizure frequency and severity in various acute seizure models.29-33 Following several successful Phase III trials, CBD has been approved by the FDA and offers a novel therapeutic option for patients with Dravet syndrome. Despite abundant evidence detailing the anticonvulsant efficacy of CBD, several commentators question CBD's intrinsic anticonvulsant activity and have attributed the positive trial outcomes to a pharmacokinetic interaction, where CBD simply increases the plasma levels and consequent efficacy of clobazam and its active metabolite, N‐CLB.12-15

What would you like to do? Message: Endorse | Bookmark | Report AbuseUser efbailey: Reward | Watch | Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.